Sorry, you need to enable JavaScript to visit this website.

Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing

TitlePrognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing
Publication TypeArticolo su Rivista peer-reviewed
Year of Publication2007
AuthorsBenevolo, M., Vocaturo A., Novelli Flavia, Mariani L., Vocaturo G., Cianciulli A.M., Marandino F., Perrone-Donnorso R., Giannarelli D., Natali P.G., and Mottolese M.
JournalAnticancer Research
Volume27
Pagination2839-2844
ISSN02507005
Keywords80 and over, accuracy, adult, aged, article, comparative study, controlled study, cytology, Endometrial Neoplasms, endometrium carcinoma, epidermal growth factor receptor 2, erbB-2, estrogen, estrogen receptor, Female, fluorescence, follow up, Follow-Up Studies, human, human cell, human tissue, Humans, immunocytochemistry, immunohistochemistry, In Situ Hybridization, major clinical study, Middle Aged, Monoclonal antibody, monoclonal antibody B.72.3, Multivariate analysis, outcome assessment, overall survival, Pathology, Peritoneal Cavity, prediction, priority journal, Progesterone, progesterone receptor, prognosis, protein expression, Receptor, Receptors, survival rate
Abstract

Background: Although the majority of endometrial cancer (EC) patients can be cured by surgery, unexpected recurrent disease may also occur in early stage patients. In the present study, whether or not the analysis of multiple biopathological parameters might lead to more accurate predictions of the clinical outcome of EC patients with long-term follow-up (FU) was investigated. Patients and Methods: Estrogen and progesterone receptor (ER and PgR) positivity and HER2 overexpression by immunohistochemistry were evaluated. The peritoneal washings (PWs) were analyzed by cytology and immunocytochemistry employing AR-3 and B72.3 monoclonal antibodies. Results: The patients with positive PW and HER2 positive tumors showed shorter overall survival compared to those bearing HER2 negative tumors (p=0.004). HER2 overexpression also influenced the patient outcome in the group with tumors lacking PgR (p=0.004). At multivariate analysis PgR and HER2 overexpression emerged as independent prognostic factors. Conclusion: The combined analysis of these biopathological markers could provide useful information for the selection of patients to be enrolled in innovative therapeutic strategies.

Notes

cited By 7

URLhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-34547758879&partnerID=40&md5=2a8d5e7c2215fdafff44678c59e8bdad
Citation KeyBenevolo20072839